UF Study: 85% of Commercial Kratom Products Have Mislabeled Alkaloid Content

Why it matters

If 85% of kratom products carry inaccurate labels, consumers cannot make informed dosing decisions — and clinicians cannot reliably counsel patients on harm reduction. The findings add scientific weight to calls for mandatory manufacturing standards and third-party testing.

The big picture

The University of Florida College of Pharmacy analyzed 44 commercially available kratom products sold online and in U.S. stores. Published in Drug Testing and Analysis, the study is among the most comprehensive chemical audits of retail kratom products to date. It comes as regulators at the state and federal level debate labeling requirements for a category of products that currently lacks FDA oversight.

Key findings

• 85% of 44 kratom products tested had measured alkaloid concentrations that did not match their labels
• Some products listed only one alkaloid but contained multiple undisclosed compounds
• Kratom leaves contain more than 40 identified alkaloids with varying pharmacological effects
• The study specifically flagged semisynthetic 7-OH products sometimes marketed simply as "kratom"
• Researchers called for stronger manufacturing standards, comprehensive testing, and transparent labeling
• The findings apply to powders, tablets, gummies, liquid shots, and other kratom-derived product forms

What they say

"Consumers should be able to trust that a product's label accurately reflects what's inside," said lead author Abhisheak Sharma, Ph.D. "Our findings show that stronger manufacturing standards, comprehensive testing and transparent labeling are needed to help people make informed decisions and reduce potential safety risks."

Bottom line

**A University of Florida study found that 85% of commercial kratom products are mislabeled, meaning most consumers have no reliable way to know what they are actually taking or at what dose.**